Literature DB >> 1116997

Abnormal induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase in leukocytes from subjects with heterozygous familial hypercholesterolemia.

A M Fogelman, J Edmond, J Seager, G Popják.   

Abstract

Human leukocytes isolated from fresh defibinated blood were shown to utilize acetate and mevalonate for sterol synthesis. The capacity of the leukocytes to synthesize sterols is limited severely as compared to their ability to convert mevalonate into farnesyl pyrophosphate (which they hydrolyze rapidly to free farnesol) and into squalene. When leukocytes are incubated in a medium containing lipid-free serum, synthesis of sterols from acetate, but not from mevalonate, is much enhanced. It was shown that this increased synthesis resulted from increased levels of 3-hydroxy-3-methylglutaryl-CoA reductase activity in the cells. A comparison was made of the activation of sterol synthesis from acetate in leukocytes of normal individuals and of heterozygous familial hypercholesterolemics. The latter group responded to incubation in lipid-free sera with a significantly higher activation than the cells of normocholesterolemics. This activation was shown to be well correlated with a higher induction of 3-hydroxy-3-methylglutaryl-CoA reductase in the heterozygous cells than in the normals. The leukocytes of a heterozygous familial hypercholesterolemic individual were found to release, into a lipid-free incubation medium, more endogenously synthesized [3H]sterol (but not [3H]squalene) than the cells of a normal person. It is suggested that the genetic abnormality in heterozygous familial hypercholesterolemia could be accounted for by a mutation resulting in a weaker binding of a sterol repressor by heterozygous cells than by normal cells.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1116997

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Regulation of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity in type II hyperlipoproteinaemia.

Authors:  D J Betteridge; M J Higgins; D J Galton
Journal:  Br Med J       Date:  1975-11-29

2.  Properties of sterol biosynthesis in human leukocytes: effects of gemfibrozil.

Authors:  D J Betteridge; M J Higgins; D J Galton
Journal:  Proc R Soc Med       Date:  1976

3.  Cholesterol synthesis in freshly isolated human leukocytes.

Authors:  P Tarugi; V Romoli; F Crovetti; S Calandra
Journal:  Experientia       Date:  1977-11-15

Review 4.  Cholesterol metabolism in man.

Authors:  S M Grundy
Journal:  West J Med       Date:  1978-01

5.  Receptor recognition of maleyl-albumin induces chemotaxis in human monocytes.

Authors:  M E Haberland; R R Rasmussen; A M Fogelman
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

6.  Scavenger receptor-mediated recognition of maleyl bovine plasma albumin and the demaleylated protein in human monocyte macrophages.

Authors:  M E Haberland; A M Fogelman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

7.  Two distinct receptors account for recognition of maleyl-albumin in human monocytes during differentiation in vitro.

Authors:  M E Haberland; R R Rasmussen; C L Olch; A M Fogelman
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  Erythrocyte contamination of leukocyte populations following density-gradient centrifugation results in artificially high levels of human leukocyte HMG-CoA reductase activity.

Authors:  H J Harwood; D M Bridge; P W Stacpoole
Journal:  Lipids       Date:  1988-12       Impact factor: 1.880

9.  Cholesterol metabolism in relation to aging and dietary fat in rats and humans.

Authors:  J Dupont; S Ewens-Luby; M M Mathias
Journal:  Lipids       Date:  1985-11       Impact factor: 1.880

10.  In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Studies in normal subjects.

Authors:  H J Harwood; D M Bridge; P W Stacpoole
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.